Lozanov B, Vurbanov V, Baleva R
Vutr Boles. 1975;14(3):103-10.
The accumulation of 131J in the thyroid gland was investigate in dynamics in 31 patients with thyrotoxicosis, treated with mercaptoimidazol (timidazol) for an average of 16 months. The patients were clinically euthyroid, with normal values of the basal metabolism, PBI, PBI131 AND TOTAL THYROXIN IN SERUM. The 131J captation, investigated in the course of a maintaining treatment without discontinuation of thyrostatics, show elevated percentages (55.4 per cent by the 6th hour, 61.3 per cent by the 24th hour), being within the norm only in eight patients. Its average values are significantly lower up to the 6th month post treatment discontinuation and closrm, with only 13 above the norm. Only three of them (10 per cent) developed recidivations till the end of the 9th month after e treatment. The authors concluded that thyrostatics, in maintaining doses, do not block thyroid gland 131J cumulation which in the majority of the cases persisted to be elevated a long time after the discontinuation. Its complete normalization in the later stages speak, most probably, for the development of a lasting remission of thyrotoxicosis.
对31例甲状腺毒症患者使用甲巯咪唑(他巴唑)平均治疗16个月后,动态研究了甲状腺中¹³¹J的蓄积情况。这些患者临床甲状腺功能正常,基础代谢、血清蛋白结合碘(PBI)、¹³¹I - PBI及总甲状腺素值均正常。在持续治疗过程中且不停用抗甲状腺药物的情况下对¹³¹J摄取进行研究,结果显示摄取百分比升高(第6小时为55.4%,第24小时为61.3%),只有8例患者在正常范围内。治疗停药后直至第6个月,其平均值显著降低,仅有13例高于正常范围。其中只有3例(10%)在治疗后第9个月末复发。作者得出结论,维持剂量的抗甲状腺药物不会阻断甲状腺对¹³¹J的蓄积,在大多数情况下,停药后很长一段时间内¹³¹J蓄积仍持续升高。后期其完全恢复正常很可能表明甲状腺毒症出现了持久缓解。